- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07711353
Transcutaneous Auricular Vagus Nerve Stimulation Added to Physiotherapy for Adhesive Capsulitis (taVNS-AC)
Effect of Transcutaneous Auricular Vagus Nerve Stimulation Added to Standard Physiotherapy on Pain, Function, and Quality of Life in Patients With Shoulder Adhesive Capsulitis: A Randomized Controlled Trial
This randomized, sham-controlled study will evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS), when added to standard physiotherapy, improves pain, shoulder function, range of motion, and quality of life in adults with adhesive capsulitis.
A total of 40 participants aged 18 to 65 years will be randomly assigned to one of two groups. Both groups will receive 15 sessions of standard physiotherapy over 3 weeks. In addition, one group will receive active taVNS for 30 minutes per day, while the other group will receive sham stimulation for the same duration and frequency. Assessments will be performed before treatment and after the 15th treatment session using pain, shoulder disability, quality-of-life, and shoulder range-of-motion measurements.
Přehled studie
Postavení
Podmínky
Detailní popis
Adhesive capsulitis is a musculoskeletal condition characterized by shoulder pain and progressive restriction of active and passive range of motion. Although physiotherapy, therapeutic exercise, and manual therapy are commonly used, pain relief and functional recovery may be incomplete in some patients. Therefore, additional non-invasive treatment approaches that may enhance the effects of rehabilitation are clinically relevant.
Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve. It may influence pain modulation, autonomic nervous system regulation, and inflammatory pathways. Previous studies have reported potential benefits of auricular vagus nerve stimulation in several chronic pain conditions; however, evidence regarding its use in adhesive capsulitis remains limited.
The objective of this study is to determine whether active taVNS added to standard physiotherapy provides greater clinical improvement than sham taVNS added to the same physiotherapy program. The main hypothesis is that participants receiving active taVNS will demonstrate greater reductions in pain and shoulder-related disability after treatment. Secondary objectives are to evaluate changes in shoulder range of motion and health-related quality of life and to assess the tolerability of the intervention.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Muhsin Doran, MD
- Telefonní číslo: 05340807940
- E-mail: muhsin-doran@hotmail.com
Studijní místa
-
-
Istanbul
-
Istanbul, Istanbul, Turecko (Türkiye), 34381
- Nábor
- Liv hospital Vadistanbul
-
Kontakt:
- Muhsin Doran, MD
- Telefonní číslo: 05340807940
- E-mail: muhsin-doran@hotmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Age between 18 and 65 years.
- Clinical diagnosis of adhesive capsulitis confirmed by physical examination and, when clinically indicated, imaging.
- Shoulder pain and limitation of shoulder range of motion for at least 3 months.
- Provision of written informed consent.
- General health status sufficient to participate in standard physiotherapy and active or sham transcutaneous auricular vagus nerve stimulation.
- Ability to comply with the planned treatment sessions and outcome assessments.
Exclusion Criteria:
- Shoulder stiffness secondary to trauma, surgery, infection, or tumor.
- Rotator cuff tear, advanced glenohumeral osteoarthritis, or inflammatory rheumatic disease.
- Glucocorticoid injection into the affected shoulder within the previous 3 months.
- Surgical intervention involving the affected shoulder within the previous 6 months.
- Active infection or skin lesion in the shoulder region.
- Cervical radiculopathy, brachial plexopathy, stroke, or another neurological disorder affecting the upper extremity.
- Presence of a cardiac pacemaker or another implanted electronic device.
- Pregnancy or breastfeeding.
- Serious systemic disease or cognitive impairment that may prevent compliance with the study protocol.
- Known intolerance or previous adverse reaction to transcutaneous electrical stimulation.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Standard Physiotherapy Plus Active taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks.
Active transcutaneous auricular vagus nerve stimulation is administered for 30 minutes during each treatment session in addition to the physiotherapy program.
|
Active transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy.
Electrical stimulation will be delivered transcutaneously through an auricular electrode to a vagally innervated region of the external ear.
The physiotherapist administering the stimulation will be aware of group allocation, while participants and the outcomes assessor will remain blinded.
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week.
The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles.
Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations.
The same physiotherapy protocol will be administered to both study arms.
|
|
Falešný srovnávač: Standard Physiotherapy Plus Sham taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks.
In addition, sham transcutaneous auricular vagus nerve stimulation is administered for 30 minutes with the same frequency and treatment schedule as the active stimulation.
|
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week.
The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles.
Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations.
The same physiotherapy protocol will be administered to both study arms.
Sham transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy.
The sham procedure will follow the same session frequency and duration as the active intervention but will be applied according to a prespecified sham protocol that is not expected to produce therapeutic vagal stimulation.
The physiotherapist administering the intervention will be aware of group allocation, while participants and the outcomes assessor will remain blinded.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Shoulder Pain and Disability Index (SPADI) Total Score
Časové okno: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
The Shoulder Pain and Disability Index (SPADI) is a 13-item patient-reported questionnaire consisting of a 5-item pain subscale and an 8-item disability subscale.
The total score ranges from 0 to 100, with higher scores indicating greater shoulder pain and disability.
The primary outcome will be the change in the SPADI total score from baseline to the assessment performed after completion of the 15th treatment session.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Shoulder Pain Intensity Assessed With the Visual Analog Scale (VAS)
Časové okno: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Shoulder pain intensity will be assessed using a 10-cm Visual Analog Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Higher scores indicate greater pain intensity.
The outcome will be calculated as the change in VAS score from baseline to the assessment performed after completion of the 15th treatment session.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
|
Change in Shoulder Flexion Range of Motion
Časové okno: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Change in Shoulder Flexion Range of Motion Change in Shoulder Abduction Range of Motion Change in Shoulder Extension Range of Motion Change in Shoulder Internal Rotation Range of Motion Change in Shoulder External Rotation Range of Motion Change in Shoulder Horizontal External Rotation Range of Motion Change in Shoulder Horizontal Abduction Range of Motion Change in Shoulder Horizontal Adduction Range of Motion
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
|
Change in Health-Related Quality of Life Assessed With the 36-Item Short Form Health Survey (SF-36)
Časové okno: Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36).
The questionnaire evaluates eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health.
Each domain is scored from 0 to 100, with higher scores indicating better health-related quality of life.
Changes in domain scores from baseline to the post-treatment assessment will be evaluated.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Muhsin Doran, Liv hospital Vadistanbul
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- LIV-FTR-taVNS-AC-2026-01
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .